IA
SIOX

Insight Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Insight Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-82,700
Closed -$232K – 351
2021
Q1 		$232K Buy
82,700
+58,700
+245% +$166K 0.07% 295
2020
Q4 		$67K Buy
+24,000
New +$69.9K 0.03% 265

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
TVWM
Tower View Wealth Management Shorewood, Wisconsin $195M AUM 29.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Insight Advisors's SIOX Position: Q2 2021 in Review

Insight Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2021, closing a stake of 82,700 shares — an estimated $232K sold.

Insight Advisors first reported a position in SIOX in Q4 2020 and held it in 2 quarters. The position peaked at $232K in Q1 2021. 54 funds tracked by Wall St. Rank hold SIOX as of Q2 2021.

  • Insight Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Insight Advisors sold 82,700 Sio Gene Therapies Inc. Common Stock shares in Q2 2021, an estimated $232K.
  • Insight Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Insight Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $232K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2021.

Based on Insight Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.